Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1).
Yeh MC, Tse BWC, Fletcher NL, Houston ZH, Lund M, Volpert M, Stewart C, Sokolowski KA, Jeet V, Thurecht KJ, Campbell DH, Walsh BJ, Nelson CC, Russell PJ.
Yeh MC, et al.
EJNMMI Res. 2020 May 7;10(1):46. doi: 10.1186/s13550-020-00637-x.
EJNMMI Res. 2020.
PMID: 32382920
Free PMC article.